East sunshine down more than 80% AbbVie original research and hit the set after the price reduction momentum is still fierce.

But Jiangsu Howson, Dongsian Pharmaceuticals, Tianfang Pharmaceuticals, AbbVie and so on have come up with full sincerity, especially the price of two drugs of Dongsian medicine dived, a drop of more than 80%.
01 after winning the bid East Sunshine drug heavy drug place re-drop documents show that the East Sunshine drug's hydrochloric acid Moxiza star tablets in Jiangsu from 45 yuan a box to 6.66 yuan a box, a decline of 85.2%.
is a fourth-generation new quinoxone antibacterial drug, mainly used to treat infections caused by sensitive bacteria in adults.
2018, China's public medical institutions Moxisha Star terminal more than 4 billion yuan market size.
, which was originally researched by Bayer, has long dominated the domestic market, but with the rise of domestic generic drug companies and the promotion of collection, the domestic market pattern of the drug is changing.
in 2019 alone, the National Drug Administration approved 10 Moxiza stars.
, Nanjing Yuke Pharmaceuticals, Chongqing Huabang Pharmaceuticals, Peking University Pharmaceuticals and Nanjing Shenghe Pharmaceuticals are 0.4g tablets.
in the second batch, the domestic generic drug companies Dongsian Pharmaceuticals, Sichuan Guowei, Chongqing Huabang, Nanjing Sheng and bay with the opportunity to split the market, Bayer fell by more than 70%.
the sun's hydrochloric acid Moxisa star won the bid at its lowest price, down 87%.
In the just-concluded third batch of collection, Moxisha Xing sodium chloride injection procurement scale reached 1,759 million yuan, Tianjin Red Day Pharmaceuticals and Hainan Aicco Pharmaceuticals won the bid, respectively, quoted 32.8 yuan, 35.27 yuan, a decrease of more than 80%, Bayer out.
the winning bid for injection preparations will be a big good for the future development of other Moxiza star dosage form business in the two enterprises.
the East Sunshine Drug actively in Jiangsu market significantly reduced prices, is undoubtedly to consolidate the market position of Moxisha Star tablets in advance.
, another product of The Sun, fell from 98 yuan to 17.08 yuan, a drop of 81.8 percent.
, a commonly used drug for lowering blood pressure, is one of 32 varieties purchased in the second batch of nationally organized drug strips.
East Sunshine Medicine won the bid at a low price of 0.11 yuan per tablet with Xinlitai (0.69 yuan per tablet), Nanjing Zhengda Tianqing (1.268 yuan per tablet) and Beijing Fuyuan Pharmaceuticals (1.7471 yuan per tablet).
02 days square metformin slow release tablets and fold, it is worth noting that Tianfang Pharmaceuticals' slow release tablets, from 24 yuan a box, down to 11.22 yuan, the price has been reduced by more than half.
in the third batch of collection, metformin oral regular release agent type procurement scale ranked third, up to 1.305 billion yuan.
metformin as a first-line sugar-lowering drug, the national market size of more than 5 billion yuan.
in the third batch, metformin entered the era of divided into units, the competition is quite fierce.
in this collection of slow release control agent type, the specifications involved is 0.5g.
Tianfang Pharmaceuticals and Qingdao Baiyang, Qingdao Huanghai Pharmaceuticals, Shanxi Huayuan Pharmaceuticals, Nanjing Yihua, Shi Pharmaceuticals Europe, Mero Pharmaceuticals, Yuekang Pharmaceuticals, Guangdong Saikang, Zhengda Tianqing and other 18 enterprises competed for the type of diocetamo slow release control agent, the highest effective declared price of 0.34 yuan.
bid price for Tianfang Pharmaceuticals was 4.35 yuan, and the price per tablet was 0.068 yuan, a decrease of 80%.
03 AbbVie Pari osteotisol injection to catch up with Hospira and this Jiangsu price reduction notice, an interesting phenomenon, AbbVie's Paripol injection (commodity resort Pule) from 340 yuan to 176 yuan.
Not long ago, on August 4th, Hospira, another manufacturer of Pari osteobolic alcohol, applied for a price reduction, and adjusted the limit price of Pari osteotisol injection (1 ml:5ug/branch) from 340 yuan/branch to 176 yuan/branch, almost hitting the discount.
it is understood that Hospira, like AbbVie, was a pharmaceutical company sped up from Abbott and later acquired by Pfizer.
orthopaedic alcohol injections are mainly used to prevent and treat secondary thyroid hyperthyroidism associated with stage 5 of chronic kidney disease.
AbbVie, the original manufacturer of Pari osteotisol injections, was approved by the FDA on April 17, 1998 and imported in China in 2013.
the first copy of Hengrui in 2018, in December 2019 Shanxi Wichida Bright Pharmaceuticals became the second domestic company to be approved.
of this year, Chengdu Yuandong Pharmaceuticals' Pari osteotisol injection 6 imitation market application was successfully approved, becoming the third in China.
products were included in the National Health Insurance Directory B in 2017, with sales of 14.1 million yuan in 2018, a growth rate of more than 600%.
2019, Henripali osteotisol in Liaoning from the original 298 yuan to 249 yuan, a decline of more than 16%.
, the price of AbbVie's Pari osteotisol injection in Jiangsu stands with Hospira for 176 yuan a year.
.